O-Desmethyl dacomitinib (PF-05199265) is the major circulating metabolite of dacomitinib ( HY-13272 ) and acts as a pan-epidermal growth factor receptor ( ErbB ) tyrosine kinase inhibitor. O-Desmethyl dacomitinib exhibits a much lower exposure level than dacomitinib in the body. O-Desmethyl dacomitinib is highly dependent on the enzymatic activity of CYP2D6 for its formation.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Drug Metabolite | Products > Signaling Pathways > EGFR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.